Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tacrolimus extended-release - Veloxis Pharmaceuticals

X
Drug Profile

Tacrolimus extended-release - Veloxis Pharmaceuticals

Alternative Names: Envarsus; Envarsus PA; EnvarsusXR; LCP-Tacro™; Tacrolimus extended release; Tacrolimus-ER

Latest Information Update: 27 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LifeCycle Pharma
  • Developer Chiesi Farmaceutici; Endo, Inc.; LifeCycle Pharma; University of Kentucky; University of Wisconsin-Madison; Veloxis Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Allotransplant rejection; Liver transplant rejection; Renal transplant rejection; Transplant rejection
  • Phase II/III Pancreas transplant rejection; Renal failure
  • Discontinued Autoimmune hepatitis

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 04 Jan 2024 Discontinued - Phase-III for Renal transplant rejection (Prevention, Treatment-naive) in France, Singapore, Serbia, New Zealand, Mexico, Sweden, Spain, Poland, Italy, South Korea, Australia, Brazil, Germany, Argentina (PO) (NCT01187953)
  • 19 Feb 2021 Phase II/III development in Renal transplant rejection and Pancreas transplant rejection (Monotherapy) is ongoing in USA (NCT03769298)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top